Literature DB >> 20689080

Stroke thrombolysis: having more time translates into delayed therapy: data from the Austrian Stroke Unit Registry.

Julia Ferrari1, Michael Knoflach, Stefan Kiechl, Johann Willeit, Benjamin Matosevic, Leonhard Seyfang, Wilfried Lang.   

Abstract

BACKGROUND AND
PURPOSE: Efficacy of intravenous thrombolysis in acute ischemic stroke declines with increasing time to treatment initiation. Previous small-scale studies suggested that the earlier patients arrive, the longer it takes to administer recombinant tissue plasminogen activator.
METHODS: Of 32 529 patients with stroke prospectively enrolled in the Austrian Stroke Unit Registry (2004 to 2009), 3287 received intravenous thrombolysis and 2663 of them were eligible for the current analysis.
RESULTS: Median (interquartile range) onset-to-door and door-to-needle times were 70 (50 to 100) and 50 (35 to 70) minutes. Of note, both time intervals were inversely correlated with each other. After adjustment for multiple stroke characteristics, the door-to-needle time of patients arriving in the hospital within the first hour after stroke onset was 6.9 minutes (P<0.001) and 13.9 minutes (P<0.001) longer than those for patients arriving between 61 to 120 and 121 to 180 minutes. Findings were consistent in subgroups.
CONCLUSIONS: Early hospital arrival translates into a significant delay in the application of intravenous thrombolysis among patients with acute stroke. This finding calls for concerted measures to ensure that all patients with stroke are treated with the same urgency irrespective of the time available.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20689080     DOI: 10.1161/STROKEAHA.110.590372

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  7 in total

1.  Delay in presentation after acute ischemic stroke: the Careggi Hospital Stroke Registry.

Authors:  Innocenti Eleonora; Nencini Patrizia; Romani Ilaria; Del Bene Alessandra; Arba Francesco; Piccardi Benedetta; Pracucci Giovanni
Journal:  Neurol Sci       Date:  2013-06-27       Impact factor: 3.307

2.  Histopathological Investigation of Different MCAO Modalities and Impact of Autologous Bone Marrow Mononuclear Cell Administration in an Ovine Stroke Model.

Authors:  Johannes Boltze; Björn Nitzsche; Kathrin D Geiger; Heinz-Adolf Schoon
Journal:  Transl Stroke Res       Date:  2011-08-23       Impact factor: 6.829

3.  Process improvement to enhance existing stroke team activity toward more timely thrombolytic treatment.

Authors:  Han-Jin Cho; Kyung Yul Lee; Hyo Suk Nam; Young Dae Kim; Tae-Jin Song; Yo Han Jung; Hye-Yeon Choi; Ji Hoe Heo
Journal:  J Clin Neurol       Date:  2014-10-06       Impact factor: 3.077

Review 4.  If Time Is Brain Where Is the Improvement in Prehospital Time after Stroke?

Authors:  Jeremy N Pulvers; John D G Watson
Journal:  Front Neurol       Date:  2017-11-20       Impact factor: 4.003

5.  Plasma midregional pro-adrenomedullin improves prediction of functional outcome in ischemic stroke.

Authors:  Thomas Seifert-Held; Thomas Pekar; Thomas Gattringer; Nicole E Simmet; Hubert Scharnagl; Christoph Bocksrucker; Christian Lampl; Maria K Storch; Tatjana Stojakovic; Franz Fazekas
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

6.  Differences in process management and in-hospital delays in treatment with iv thrombolysis.

Authors:  Julia Ferrari; Michael Knoflach; Leonhard Seyfang; Wilfried Lang
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

7.  Positive impact of the participation in the ENCHANTED trial in reducing Door-to-Needle Time.

Authors:  Jie Yang; Xia Wang; Jian Ping Yu; Jing Hang; Pablo Lavados; Thompson Robinson; Hisatomi Arima; Richard I Lindley; Craig S Anderson; John Chalmers
Journal:  Sci Rep       Date:  2017-10-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.